295
Participants
Start Date
March 31, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
May 31, 2008
Levodopa (Pardoprunox)
12-42mg
Placebo Comparator
Placebo
Site 223, Birmingham
Site 220, La Jolla
Site 211, San Francisco
Site 214, Fort Lauderdale
Site 218, Gainsville
Site 213, Tampa
Site 219, Augusta
Site 221, Chicago
Site 216, Kansas City
Site 224, Lexington
Site 212, East Lansing
Site 217, St Louis
Site 222, Durham
Site 210, Toledo
Site 215, Houston
Site 100, Buenos Aires
Site 101, Buenos Aires
Site 102, Buenos Aires
Site 103, Buenos Aires
Site 106, Buenos Aires
Site 107, Buenos Aires
Site 109, Buenos Aires
Site 105, Córdoba
Site 104, Mar del Plata
Site 108, Santa Fe
Site 114, Alto da Glória
Site 113, Belo Horizonte
Site 112, Campinas
Site 116, Marília
Site 111, Porto Alegre
Site 118, Porto Alegre
Site 117, Ribeirão Preto
Site 119, Salvador
Site 110, São Paulo
Site 115, São Paulo
Site 125, São Paulo
Site 123, Plovdiv
Site 120, Sofia
Site 121, Sofia
Site 122, Sofia
Site 124, Sofia
Site 136, Calgary
Site 137, Greenfield Park
Site 133, Halifax
Site 132, Markham
Site 130, Montreal
Site 134, Ottawa
Site 138, Peterborough
Site 135, Sainte-Anne
Site 139, Toronto
Site 131, Windsor
Site 140, Santiago
Site 141, Santiago
Site 143, Santiago
Site 142, Valdivia
Site 151, Bogotá
Site 152, Bogotá
Site 153, Bogotá
Site 154, Bogotá
Site 150, Medellín
Site 160, Riga
Site 172, Kaunas
Site 170, Vilnius
Site 171, Vilnius
Site 184, Bellavista Callao
Site 180, Lima
Site 181, Lima
Site 182, Lima
Site 183, Lima
Site 193, Kazan'
Site 190, Moscow
Site 194, Moscow
Site 197, Moscow
Site 191, Saint Petersburg
Site 192, Saint Petersburg
Site 195, Saint Petersburg
Site 198, Saint Petersburg
Site 196, Yaroslavl
Site 204, Dnipro
Site 206, Kharkiv
Site 201, Kyiv
Site 202, Kyiv
Site 205, Lviv
Site 203, Poltava
Site 208, Simferopol
Site 200, Vinnitsa
Site 207, Zaporizhya
Solvay Pharmaceuticals
INDUSTRY